Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)    
Revenues, net $ 40,442 $ 20,518
Operating expenses:    
Cost of implants and other costs 8,676 1,535
Research and development 237,387 197,849
Selling, general and administrative 796,049 938,945
Impairment of intellectual property 47,980 0
Depreciation and amortization 6,665 6,863
Total operating expenses 1,096,757 1,145,192
Loss from operations (1,056,315) (1,124,674)
Other income (expenses):    
Interest expense - related parties (169,380) (153,500)
Interest expense, net (26,040) (13,276)
Grant income 241,149 346,393
Other miscellaneous income 0 66
Total other income 45,729 179,683
Net loss before provision for income taxes (1,010,586) (944,991)
Income taxes 0 0
Net loss (1,010,586) (944,991)
Non-controlling interest 934 551
Net loss attributable to BioCorRx Inc. $ (1,009,652) $ (944,440)
Net loss per common share, basic and diluted $ (0.13) $ (0.14)
Weighted average number of common shares outstanding, basic and diluted 7,741,681 6,931,759